Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 31686034.
- Also identified by DOI 10.1038/s41591-019-0611-3 and PMC identifier 6898984.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We identified a PSEN1 (presenilin 1) mutation carrier from the world's largest autosomal dominant Alzheimer's disease kindred, who did not develop mild cognitive impairment until her seventies, three decades after the expected age of clinical onset. The individual had two copies of the APOE3 Christchurch (R136S) mutation, unusually high brain amyloid levels and limited tau and neurodegenerative measurements. Our findings have implications for the role of APOE in the pathogenesis, treatment and prevention of Alzheimer's disease.
Medical subject headings
- Alzheimer Disease
- Apolipoprotein E3
- Neurodegenerative Diseases
- Presenilin-1